An online training program designed to reduce prescription drug abuse shows promise in early results, HealthCanal reports.
People who live in counties with higher concentrations of dentists and pharmacists are at increased risk of abusing prescription opioids, a new study suggests.
In an effort to eliminate or reduce opioid abuse, Dr. Timothy Deer, President and CEO of The Center for Pain Relief, explains various pain treatment options physicians and patients should consider.
Doctors are trying a new approach to pain management after surgery, in an attempt to reduce patients’ reliance on narcotic painkillers, according to The Wall Street Journal.
The Food and Drug Administration on Friday approved the first pure hydrocodone drug in the United States. The drug, Zohydro ER (extended release), was approved for patients with pain that requires daily, around-the-clock, long-term treatment that cannot be treated with other drugs.
Business and patient groups waged a costly lobbying campaign against tighter prescribing regulations for hydrocodone products for many years, according to The New York Times. Last week, the Food and Drug Administration recommended tighter restrictions for products containing hydrocodone and other painkillers such as acetaminophen or aspirin.
The Food and Drug Administration has recommended tighter restrictions for products containing hydrocodone and other painkillers such as acetaminophen or aspirin. These combination products include Vicodin and Lortab.
A new study suggests patients taking buprenorphine to treat their opioid addiction may benefit from tapering off the medication over four weeks instead of a shorter period. The longer detoxification is effective when it is followed by treatment with naltrexone, a drug that blocks opioid strength, the researchers found.
Addiction treatment experts urged New Jersey legislators last week to take steps to curb opioid abuse, including expanding what doctors are required to learn about addiction, and making participation in the state’s prescription drug monitoring program mandatory.
Reproduction in whole or in part of this publication is strictly prohibited without prior consent. Photographic rights remain the property of Join Together and the Partnership for Drug-Free Kids. For reproduction inquiries, please e-mail email@example.com.